Consortium board

Jennifer Keiser

Jennifer Keiser is an Assistant Professor at the Department of Medical Parasitology and Infection Biology at the Swiss Tropical and Public Health Institute (Swiss TPH). She is heading the Helminth Drug Development Unit, which maintains many helminth rodent models including Schistosoma mansoni. Research objectives of her team include in vitro and in vivo evaluation of compounds, preclinical studies such as pharmacokinetics and metabolism, mechanism of action studies and clinical trials in endemic countries.

Ton Rijnders

Ton Rijnders became Scientific Director of Lygature (formerly Top Institute Pharma) in 2011. He started his career in industry at Organon in 1986, where he held several management positions. After the acquisition by Schering-Plough and later Merck, he was appointed VP Discovery and Site Head Oss. Ton Rijnders holds a PhD in Molecular Biology, and is member of several scientific and professional societies. In addition, from 2013 onwards Ton is also Head of the European Screening Centre, part of the IMI European Lead Factory.  

Kathleen Ford

Based in the US, Kathleen Ford is Senior Vice President, Head of Global Clinical Operations within the healthcare business of Merck KGaA, Darmstadt, Germany. She has more than 20 years of biopharmaceutical experience supporting pipeline development with positions in Clinical Operations in multiple biopharma companies as well as with CRO organizations. She holds a Bachelor of Science in Nursing with graduate work in the Health Policy doctoral program at Brandeis University, Waltham MA.

Peter Bonate has more than 20 years industry experience and is currently the Executive Director of the Pharmacokinetics, Modeling, & Simulation Group at Astellas.  He has a PhD in Medical Neurobiology, an MS in Statistics, and an MS in Pharmacology/Toxicology.  He is a fellow of the American Association of Pharmaceutical Scientists (AAPS) and American College of Clinical Pharmacology.  An expert in clinical pharmacology and the mathematical modeling of clinical and pharmacokinetic data, in 2015, he was the recipient of the Clinical Pharmacology and Translation Research Achievement Award from AAPS.

Daniel Lacerda de Oliveira joined Farmanguinhos in 2006 and is currently Project manager in Research & Development, managing both technical and operational teams. Prior to that he was Head of the Laboratory of Pharmaceutical Technology and a Specialist in development of drug formulation. Working since 2001 in various departments in the Pharmaceutical Industry he has extensive knowledge of pharmaceutical legislation, involving registration, post-registration changes and GMP."